Saturday, 20 July 2024

Australia's most trusted
source of pharma news

Saturday, 20 July 2024
Listen to this story 

Mundi faces HCP tobacco boycott

Posted 10 July 2024 AM

The Thoracic Society of Australia and New Zealand (TSANZ) has cut ties with Mundipharma and warned a backlash from its members could include deprescribing all the company's products after the pharma entered a new deal with inhaled medicines specialist, Vectura, which is owned by tobacco giant Philip Morris International (PMI). 

In April, Mundipharma announced a 'collaboration agreement' with Vectura for the reformulation of its asthma product Flutiform. The decision has caused outrage, with the peak body - which has an 1800 strong membership, more than half of whom are respiratory specialists - taking a stand against the company.

To see the whole article, please login

Latest Jobs
Pharma in Focus  Jobs

Sales & Customer Relations (15)

Clinical & Medical, R&D (15)

Regulatory, Pharmacovigilance & QA (9)

Other (28)

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.